Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression

Carcinogenesis

Volumn 35, Issue 4, 2014, Pages 859-866

  Palagani, Vindhya ^a   Bozko, Przemyslaw ^a   El khatib, Mona ^a   Belahmer, Hanane ^a   Giese, Nathalia ^b   Sipos, Bence ^a   Malek, Nisar P ^a   Plentz, Ruben R ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; GAMMA SECRETASE INHIBITOR; GAMMA SECRETASE INHIBITOR IX; JANUS KINASE; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; NOTCH RECEPTOR; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ACINAR DUCTAL METAPLASIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL MIGRATION; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT TRANSFORMATION; METAPLASIA; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; PROTEIN INDUCTION, SYNTHESIS AND MODIFICATION; PROTEIN INHIBITION; SIGNAL TRANSDUCTION; THERAPY EFFECT; TUMOR INVASION;

CELL LINE, TUMOR; DISEASE PROGRESSION; HUMANS; NEOPLASMS; PROTEIN KINASES; RECEPTORS, NOTCH; STAT TRANSCRIPTION FACTORS;

EID: 84898607876     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt394     Document Type: Article

References (38)

1. Jemal, A. et al. (2010) Cancer statistics, 2010. CA. Cancer J. Clin., 60, 277-300.
2. Hezel, A.F. et al. (2006) Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev., 20, 1218-1249.
3. Vincent, A. et al. (2011) Pancreatic cancer. Lancet, 378, 607-620.
4. Hidalgo, M. (2010) Pancreatic cancer. N. Engl. J. Med., 362, 1605-1617.
5. Stathis, A. et al. (2010) Advanced pancreatic carcinoma: current treatment and future challenges. Nat. Rev. Clin. Oncol., 7, 163-172.
6. Conroy, T. et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med., 364, 1817-1825.
7. Jones, S. et al. (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science, 321, 1801-1806.
8. Koch, U. et al. (2010) Notch signaling in solid tumors. Curr. Top. Dev. Biol., 92, 411-455.
9. Artavanis-Tsakonas, S. et al. (1999) Notch signaling: cell fate control and signal integration in development. Science, 284, 770-776.
10. Apelqvist, A. et al. (1999) Notch signalling controls pancreatic cell differentiation. Nature, 400, 877-881.
11. Miyamoto, Y. et al. (2003) Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell, 3, 565-576.
12. Plentz, R. et al. (2009) Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma. Gastroenterology, 136, 1741-1749.
13. Mullendore, M.E. et al. (2009) Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin. Cancer Res., 15, 2291-2301.
14. Büchler, P. et al. (2005) The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann. Surg., 242, 791-800.
15. Wang, Z. et al. (2006) Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol. Cancer Ther., 5, 483-493.
16. Hingorani, S.R. et al. (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell, 4, 437-450.
17. De La O, J.P. et al. (2008) Notch and Kras reprogram pancreatic acinar cells to ductal intraepithelial neoplasia. Proc. Natl Acad. Sci. USA, 105, 18907-18912.
18. Mazur, P.K. et al. (2010) Notch2 is required for progression of pancreatic intraepithelial neoplasia and development of pancreatic ductal adenocarcinoma. Proc. Natl Acad. Sci. USA, 107, 13438-13443.
19. Mizuma, M. et al. (2012) The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Mol. Cancer Ther., 11, 1999-2009.
20. Cook, N. et al. (2012) Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma. J. Exp. Med., 209, 437-444.
21. Scholz, A. et al. (2003) Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology, 125, 891-905.
22. Toyonaga, T. et al. (2003) Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett., 201, 107-116.
23. Zhong, Z. et al. (1994) Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science, 264, 95-98.
24. Shuai, K. et al. (1994) Interferon activation of the transcription factor Stat91 involves dimerization through SH2-phosphotyrosyl peptide interactions. Cell, 76, 821-828.
25. Yu, H. et al. (2004) The STATs of cancer-new molecular targets come of age. Nat. Rev. Cancer, 4, 97-105.
26. Chan, K.S. et al. (2004) Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J. Clin. Invest., 114, 720-728.
27. Luna, J. (2002) Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene, 21, 7611-7618.
28. Wang, T. et al. (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med., 10, 48-54.
29. Frank, D.A. (2007) STAT3 as a central mediator of neoplastic cellular transformation. Cancer Lett., 251, 199-210.
30. Corcoran, R.B. et al. (2011) STAT3 plays a critical role in KRAS-induced pancreatic tumorigenesis. Cancer Res., 71, 5020-5029.
31. Miyatsuka, T. et al. (2006) Persistent expression of PDX-1 in the pancreas causes acinar-to-ductal metaplasia through Stat3 activation. Genes Dev., 20, 1435-1440.
32. Jia, J. et al. (2013) Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer. Anticancer. Drugs, 24, 237-250.
33. Nam, S. et al. (2013) Dual inhibition of Janus and Src family kinases by novel indirubin derivative blocks constitutively-activated Stat3 signaling associated with apoptosis of human pancreatic cancer cells. Mol. Oncol., 7, 369-378.
34. Huang, S. et al. (2013) Dual targeting of EGFR and HER3 with MEHD7945A overcomes acquired resistance to EGFR inhibitors and radiation. Cancer Res., 73, 824-833.
35. Kamakura, S. et al. (2004) Hes binding to STAT3 mediates crosstalk between Notch and JAK-STAT signalling. Nat. Cell Biol., 6, 547-554.
36. Doucas, H. et al. (2008) Expression of nuclear Notch3 in pancreatic adenocarcinomas is associated with adverse clinical features, and correlates with the expression of STAT3 and phosphorylated Akt. J. Surg. Oncol., 97, 63-68.
37. Gozgit, J.M. et al. (2008) Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J. Biol. Chem., 283, 32334-32343.
38. Jin, S. et al. (2013) Non-canonical Notch signaling activates IL 6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKa/IKKb. Oncogene, 32, 4892-4902.